Entering text into the input field will update the search result below

CytomX shares plummet 28% on phase 2 study of breast cancer antibody praluzatamab

Jul. 06, 2022 4:19 PM ETCytomX Therapeutics, Inc. (CTMX)By: Anuron Mitra, SA News Editor2 Comments

Love, Health Care, Donation and Charity Concept. Breast Cancer Awareness. World Cancer Survivor Day


  • CytomX Therapeutics (NASDAQ:CTMX) shares plummeted 28% in after-hours trading on Wednesday after the company released phase 2 trial results of its antibody praluzatamab ravtansine in breast cancer.
  • CTMX said the study met the primary endpoint of objective response rate of greater than

Recommended For You

Comments (2)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

Nothing ever worked from this company .
This company really is the biggest sh*tshow in biotech. What a disgrace
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.